Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$3.32M+1169.60%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Arnon Rosenthal
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 103
- Beta
- 0.62
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -7.40
Financials
Revenue
$3.32M+1169.6%Net Income
$-22.99MEBITDA
$-20.81MFree Cash Flow
$-34.25MEPS (diluted)
$-0.21Shares Outstanding (diluted)
111.22M+1208.9%Operating Expenses
$27.71MCash & Debt
$172.80MReturn of Capital
$0.00Revenue by Segment (annual)
$173.40MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $21.05M | $-142.93M | $-1.39 |
| 2024 | $100.56M | $-119.05M | $-1.23 |
| 2023 | $97.06M | $-130.39M | $-1.56 |
| 2022 | $133.62M | $-133.31M | $-1.62 |
| 2021 | $207.09M | $-36.33M | $-0.45 |
| 2020 | $21.10M | $-190.23M | $-2.45 |
| 2019 | $21.22M | $-105.39M | $-1.62 |
| 2018 | $27.68M | $-52.25M | $-0.76 |
| 2017 | $3.73M | $-32.48M | $-0.63 |
| 2016 | $416.0K | $-15.11M | $-1.78 |
Valuation
ALEChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·3d ago·Negative
Alector Announces Pricing of Underwritten Offering SOUTH SAN FRANCISCO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (“Alector,” Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the pricing of an underwritten offering of common stock. Alector is selling 36,600,000 shares of common stock. The shares of common stock are being sold at an offering price of $2.05 per share, which represent…
View source ↗ - Newsseekingalpha.com·6d ago·Positive
Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript
View source ↗ - Newsmarketbeat.com·6d ago·Neutral
Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's Therapies Alector NASDAQ: ALEC outlined its strategy to advance brain-penetrant therapies for neurodegenerative diseases, highlighting an anti-amyloid beta antibody for Alzheimer's disease and two siRNA programs targeting tau and alpha-synuclein.
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson's Disease and Other Neurodegenerative Diseases Alector grants Genentech exclusive rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy (ERT) enabled by Alector Brain Carrier (ABC), Alector's proprietary blood-brain barrier delivery platform
View source ↗ - Newsseekingalpha.com·34d ago·Positive
Alector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Alector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·34d ago·Neutral
Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
Alector to Participate in Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 (New York, New York) Thursday, September 10, 2026, at 2:10 p.m.
View source ↗
Earnings
Thu, Nov 5(in 2 weeks)
Consensus estimate $-0.23 per share
Typical surprise +19.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.21 vs $-0.23beat
- Thu, May 7$-0.21 vs $-0.35beat
- Wed, Feb 25$-0.34 vs $-0.39beat
- Thu, Nov 6$-0.34 vs $-0.42beat
- Thu, Aug 7$-0.30 vs $-0.45beat
- Thu, May 8$-0.41 vs $-0.44beat
Estimates and results for ALEC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALEC officers and directors.
- Bought
- —
- Sold
- $1.1m
0 trades
23 trades
- Wong-sarad Gracesold
- Wong-sarad Gracesold
- Berkley Neil Lindsaysold
- Rosenthal Arnonsold
- Wong-sarad Gracesold
- Wong-sarad Gracesold
- Wong-sarad Gracesold
- Wong-sarad Gracesold
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ALEC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.